Pharmaceuticals
111, Inc. Announces Second Quarter 2023 Unaudited Financial Results
SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the second quar...
2023-08-24 14:00
3189
PeptiGrowth Inc. and Orizuru Therapeutics, Inc. Enter into Joint Development of Novel Synthetic Peptide Based Growth Factor
TOKYO, Aug. 23, 2023 /PRNewswire/ -- PeptiGrowth Inc (PeptiGrowth), a Japanese biotechnology company focusing on the development of synthetic peptide based growth factors and Orizuru Therapeutics, Inc(OZTx), a Japanese biopharmaceutical company focusing on the research and development of iPSC-de...
2023-08-24 09:51
1639
Everest Medicines Announces Interim Results for First Half of 2023
SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2023, ...
2023-08-24 08:15
4225
Samsung Biologics appoints new leadership to oversee quality and regulatory affairs
- Distinguished industry leaders with extensive track records in quality assurance and regulatory affairs join Samsung Biologics to support the company's quality-driven business operation. INCHEON, South Korea, Aug. 23, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract d...
2023-08-24 07:59
1743
Innovent Announces 2023 Interim Results and Business Updates
Remarkable achievements with accelerated growth and improved efficiency to underpin sustainable growth ROCKVILLE, M.D. and SUZHOU, China, Aug. 23, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and comme...
2023-08-23 19:38
4648
Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company
MELBOURNE, Australia, Aug. 23, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended30 June 2023. All figures are in AUD$ unless otherwise stated.[1] Financial highlights * Total Group revenue $220.8M ...
2023-08-23 17:40
1439
USANA Philippines Celebrates Legacy of Wellness Empowerment With Enterprise Asia Linchpin of Asia Awards 2023
SINGAPORE, Aug. 22, 2023 /PRNewswire/ -- Founded in 1992 by microbiologist and immunologist Dr. Myron Wentz, USANA Health Sciences is a U.S.-based international direct-selling company that researches, manufactures, and sells premium, science-based supplements, personal care, and healthy living...
2023-08-23 17:06
1668
Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill
SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm
Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome
Hair Fill. HAIRNA Exosome Hair Fill is developed with Maypharm's exclusive
technology for scalp rejuvenation and hair growth.
2023-08-23 17:00
1548
ImmVira Appoints Howard L. Kaufman, M.D. as Consulting Medical Advisor
SHENZHEN, China, Aug. 22, 2023 /PRNewswire/ -- ImmVira announced to appoint Dr. Howard L. Kaufman as Consulting Medical Advisor. Dr. Kaufman's expertise in scientific research and clinical development, especially in the areas of oncolytic virus and immunotherapy, will greatly enhance ImmVira's re...
2023-08-23 10:51
1786
Lynk Pharmaceuticals Announces Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Ankylosing Spondylitis
HANGZHOU, China, Aug. 23, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (referred to as "Lynk Pharmaceuticals"), an innovative clinical stage company, announced positive topline data from a Phase II clinical trial of LNK01001 for the treatment of ankylosing spondylitis (AS). The study, led...
2023-08-23 08:00
3177
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure First of several studies to investigate the potential of BRII-179 in enriching patients with strong intrinsic anti-HBsAg responses for curative treatments to start before the end ...
2023-08-22 22:00
3438
Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization
SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH) – a global innovative pharmaceutical company specializing in the discovery, development and commercialization of innovative drugs that treat genitourinary (GU) tumors and other related diseases – today release...
2023-08-22 20:58
2250
Sanyou Biopharmaceuticals and Sinorda Biomedicine signed Strategic Cooperation Agreement for Advancing Innovative Drug Research and Development
SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "Sanyou" hereafter) and Sinorda Biomedicine (referred to as " Sinorda " hereafter) have officially signed a strategic cooperation agreement to advance the innovative bispecific antibody drug pro...
2023-08-22 20:00
1824
CARsgen Announced 2023 Interim Results
SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Interim Results. Business Highlights * Collaboration agr...
2023-08-22 19:30
3386
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
SUZHOU, China, Aug. 22, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 180 patients for the Phase...
2023-08-22 17:13
1619
Introducing NeoMab™: GemPharmatech's Innovative Antibody Gene Humanized Mouse Model
SAN DIEGO, Aug. 21, 2023 /PRNewswire/ -- GemPharmatech is proud to announce the launch of NeoMab™, our independently developed fully antibody gene humanized mouse model, after four years of rigorous research and validation. NeoMab™ is specifically designed to meet the burgeoning therapeutic antib...
2023-08-22 08:59
1514
CanariaBio Achieves Significant Milestone with FDA's Orphan Drug Designation for MAb-AR20.5 Targeting Pancreatic Cancer
The investigational monoclonal antibody becomes the first to target Mucin 1 (MUC1) and receive this designation. PYEONGTAEK, South Korea, Aug. 21, 2023 /PRNewswire/ -- CanariaBio Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative immun...
2023-08-21 20:00
1839
Hummingbird Bioscience to Present Poster on HMBD-001 Combination Strategy for Squamous Non-Small Cell Lung Cancer at World Conference on Lung Cancer 2023
HOUSTON and SINGAPORE, Aug. 21, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced an upcoming poster presentation at the IASLC 2023 World Conference ...
2023-08-21 17:58
1625
Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon® for the Treatment of IgA Nephropathy
SHANGHAI, Aug. 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced today that U.S. Food and Drug Administration (FDA) has accepted the submission for the supplemental New Drug Application (sNDA) for Nefecon® from its partner Calliditas Therapeutics AB ...
2023-08-21 08:20
2129
TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination
NEW YORK, Aug. 18, 2023 /PRNewswire/ -- TradeUP Acquisition Corp. (the "Company" or "TradeUP") (NASDAQ: UPTD) today announced that, in order to extend the date by which the Company must complete its initial business combination fromAugust 19, 2023 to September 19, 2023, for each public share that...
2023-08-19 04:30
5238
Week's Top Stories
Most Reposted
ASTON MARTIN ARAMCO FORMULA ONE® TEAM ANNOUNCE PEPPERSTONE AS OFFICAL TRADING PARTNER
[Picked up by 308 media titles]
2025-01-07 09:00
Brewing Connections and Spotlighting Café Culture: MIFB 2025 Hosts MNCC in Collaboration with MSCA
[Picked up by 307 media titles]
2025-01-06 14:00
RuggON Unveils VORTEX Vehicle Mount Computer with AI-Enhanced, SATCOM-Ready
[Picked up by 306 media titles]
2025-01-06 21:00
iWOW Unveils Age-Tech Innovations at CES 2025, Expanding Portfolio of IoT Solutions for Ageing-In-Place
[Picked up by 294 media titles]
2025-01-07 21:18CELEBRATE THE LUNAR NEW YEAR 2025 AT HOIANA RESORT & GOLF, WORLD'S LEADING FULLY INTEGRATED RESORT
[Picked up by 292 media titles]
2025-01-06 19:25
Most Read
Interest-Driven Consumption Sparks ¥ 500B ACG Goods Market, MINISO Rides the Wave
2025-01-03 19:33
10992
